Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Harvard Bioscience (HBI0) Stock Price & Analysis

1 Followers

HBI0 Stock Chart & Stats

€4.08€0.00(0.00%)
At close: 5:30 PM GMT+1
€4€6Oct 17Nov 3Nov 17Dec 1Dec 16Dec 29Jan 13
Day’s Range
EUR 4.08 - EUR 4.30
52-Week Range
EUR 3.90 - EUR 7.20
Previous Close
EUR 4.08
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 38.23M
Enterprise Value
EUR 75.56M
Total Cash (Recent Filing)
EUR 4.86M
Total Debt (Recent Filing)
EUR 44.29M
Price to Earnings (P/E)
―
Beta
1.38
Next Earnings
Mar 11, 2027 (Est.)
EPS Estimate
-0
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Recurring Revenue Base

A recurring revenue base of about 54% gives Harvard Bioscience repeat demand from installed workflows and routine laboratory use. This can make revenue more resilient than relying solely on infrequent capital-equipment purchases and supports ongoing customer relationships over the next several quarters.

Broad Product And Customer Demand

Growth across multiple customer groups and product categories indicates that momentum is not dependent on one narrow application. Continued CRO, biopharma and preclinical demand can broaden the company’s revenue base, improve utilization of its commercial platform, and support durable adoption of its research tools.

Project Viking Savings

The manufacturing-consolidation program offers a defined path to structural cost reduction rather than a temporary benefit. If completed as planned, recurring savings should improve gross margin and adjusted EBITDA, strengthen operating leverage, and provide greater internal resources for product development and debt management.

Bears Say

High Financial Leverage

A materially weakened equity base relative to debt reduces financial flexibility and increases the company’s sensitivity to operating setbacks. Persistent losses could make deleveraging harder, while the elevated leverage burden may constrain investment, acquisitions, and other capital-allocation choices.

Negative Cash Generation

Current cash generation is not yet supporting the business, with negative operating and free cash flow following stronger performance in earlier periods. Continued cash consumption can increase reliance on debt or working-capital actions and limits the company’s ability to fund growth while profitability remains weak.

Profitability And Mix Pressure

The reduced EBITDA outlook shows that revenue growth is not currently translating consistently into earnings growth. Greater exposure to lower-margin legacy products, distribution channels and China can dilute profitability, making sustainable operating improvement dependent on mix changes, cost control, and successful new-product adoption.

Harvard Bioscience News

HBI0 FAQ

What was Harvard Bioscience’s price range in the past 12 months?
Harvard Bioscience lowest stock price was €3.90 and its highest was €7.20 in the past 12 months.
What is Harvard Bioscience’s market cap?
Harvard Bioscience’s market cap is €38.23M.
When is Harvard Bioscience’s upcoming earnings report date?
Harvard Bioscience’s next earnings report is estimated for Mar 11, 2027 (not yet confirmed), which is in 117 days.
How were Harvard Bioscience’s earnings last quarter?
Harvard Bioscience released its earnings results on Nov 10, 2026. The company reported -€0.054 earnings per share for the quarter, beating the consensus estimate of -€0.299 by €0.245.
Is Harvard Bioscience overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Harvard Bioscience pay dividends?
Harvard Bioscience does not currently pay dividends.
What is Harvard Bioscience’s EPS estimate?
Harvard Bioscience’s EPS estimate is -0.00.
How many shares outstanding does Harvard Bioscience have?
Harvard Bioscience has 4,573,080 shares outstanding.
What happened to Harvard Bioscience’s price movement after its last earnings report?
Harvard Bioscience reported an EPS of -€0.054 in its last earnings report, beating expectations of -€0.299. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Harvard Bioscience?
Hedge funds hold Harvard Bioscience shares: the largest hedge-fund position in Harvard Bioscience is 207,745,466 shares, and hedge funds decreased their holdings by 5.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology